ADAP Stock Forecast 2024: Adaptimmune Therapeutics Plc ADR Remains Weak With A Upside Of 57.14%
In the last trading session, 1.48 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.50. Most recently the